Marcia S. Brose

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

• Efficacy and safety of pralsetinib in advanced or metastatic <i>RET</i> -altered thyroid cancer (TC): Final analysis of the phase 1/2 ARROW study.

  Journal of Clinical Oncology · 2026-05-27

• Cabozantinib versus placebo in patients with radioiodine-refractory differentiated thyroid cancer after prior vascular endothelial growth factor receptor-targeted therapy (COSMIC-311): outcomes by BRAF status

  Frontiers in Oncology · 2026-03-04

• Patient-Reported Tolerability of Selpercatinib Compared to Cabozantinib/Vandetanib: A Secondary Analysis of the LIBRETTO-531 Randomized-Controlled Trial in <i>RET</i> -Mutant Medullary Thyroid Cancer

  Thyroid · 2025-08-18 · 4 citations

• Well-Differentiated Lung Neuroendocrine Tumor Masquerading as Metastatic Medullary Thyroid Cancer

  JCEM Case Reports · 2025-07-14

• Efficacy and safety of larotrectinib in patients with TRK fusion thyroid carcinoma: An updated analysis.

  Journal of Clinical Oncology · 2025-05-28

• Larotrectinib Compared With Real-World Non–Tropomyosin Receptor Kinase Inhibitor Therapies in Patients With Tropomyosin Receptor Kinase Fusion Cancer

  JCO Precision Oncology · 2025-04-01 · 2 citations

• Assessing tolerability with the Functional Assessment of Cancer Therapy item GP5: psychometric evidence from LIBRETTO-531, a phase 3 trial of selpercatinib in medullary thyroid cancer

  Journal of Patient-Reported Outcomes · 2024-12-18 · 4 citations

• A plain language summary looking at how well larotrectinib works and how safe it is for people with TRK fusion-positive thyroid cancer

  Future Oncology · 2024-11-29 · 1 citations

• 98 (PB086): First-in-human, phase 1 study of a selective RET inhibitor, LOXO-260, in patients with RET inhibitor refractory, RET-altered cancers

  European Journal of Cancer · 2024-10-01

• Durability of Response With Selpercatinib in Patients With <i>RET</i>-Activated Thyroid Cancer: Long-Term Safety and Efficacy From LIBRETTO-001

  Journal of Clinical Oncology · 2024-08-02 · 47 citations